Gluten Intolerance Treatment Market - Top Companies and Manufacturers

Companies Dominating the Gluten Intolerance Treatment Landscape

Takeda Pharmaceutical Company Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

ActoBio Therapeutics, Inc.
Precigen, Inc.
Calypso Biotech BV
ImmunogenX, Inc.
Alvine Pharmaceuticals
Dr. Falk Pharma GmbH
ImmusanT, Inc.
Zedira GmbH
FunZyme BioTechnologies S.A.
Amyra Biotech AG

Browse Key Market Insights with Data Illustration:

Gluten Intolerance Treatment Market Size Forecasts 2035

In the News

ActoBio Therapeutics, Inc., a wholly-owned subsidiary of Intrexon Corporation announced that the U.S. Food and Drug Administration (FDA) has given its permission to an Investigational New Drug (IND) application for AG017. It is an innovative orally-delivered therapeutic candidate for the treatment of celiac disease.
Takeda Pharmaceutical Company Limited, Zedira GmbH and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227. TAK-227 is a Phase 2b investigational therapy for the treatment of celiac disease designed to prevent the immune response to gluten in celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage to the small intestine.

Frequently Asked Questions (FAQ)

The growing prevalence of autoimmune, allergic, and non-autoimmune-allergic GRDs and the rising damage of gut flora are the major factors driving the growth of the gluten intolerance treatment market.

The market of gluten intolerance treatment is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023 â€“ 2035.

The major players in the market are Precigen, Inc., ImmunogenX, Inc., Calypso Biotech BV, Zedira GmbH, and FunZyme BioTechnologies S.A.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type. gluten-related disorders, distribution channel, and region.

The celiac disease segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Challenges in diagnoses are estimated to be the growth hindering factors for the market expansion.

The market in the Europe region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

Gluten Intolerance Treatment Market - Top Companies and Manufacturers

Companies Dominating the Gluten Intolerance Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the gluten intolerance treatment market?

What would be the CAGR of the gluten intolerance treatment market over the forecast period?

Who are the major players dominating the gluten intolerance treatment market?

How are the company profiles selected?

What are the segments in the gluten intolerance treatment market?

Which segment captures the largest market size in the gluten-related disorders segment in the gluten intolerance treatment market?

What are the challenges affecting the market growth?

Which region will provide more business opportunities for the growth of the gluten intolerance treatment market in the future?